Phase 2 PTSD Trial, Recruiting NCT05889741 Sponsor: The University of Texas Health Science Center at San Antonio Condition: PTSD
Back to Ptsd

Phase 2 PTSD Trial, Recruiting

NCT05889741
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are active duty or retired military service members between 18 and 65 years old
  • People who have been diagnosed with PTSD, confirmed through a structured clinical assessment called the Clinician-Administered PTSD Scale
  • People who are able to speak and read English, as the study measures have been standardised in English
  • People who are registered in the Defense Enrollment Eligibility Reporting System (DEERS) and are eligible to receive care at a military treatment facility where the procedure would be performed (confirm with trial site)

Who may not be able to join:

  • People who are currently experiencing serious thoughts of suicide that need immediate attention, as assessed by clinical tools and confirmed by a credentialed provider
  • People who are currently experiencing a manic episode or psychotic symptoms that require immediate treatment or hospitalisation
  • People who are currently experiencing moderate to severe problems with substance use, including alcohol, that require immediate intervention
  • People who have another psychiatric condition that is considered more significant than PTSD, based on a clinician's assessment
  • People who are currently pregnant or breastfeeding
  • People who are currently taking blood-thinning medications
  • People who have a history of a bleeding disorder
  • People who have an infection or growth at the site where the injection would be given
  • People who have had a heart attack within the 6 months before the procedure
  • People who have an abnormally slow heart rate or irregular heart rhythms
  • People who have low blood pressure that causes symptoms
  • People who have paralysis or impairment of the phrenic or laryngeal nerves (confirm with trial site)
  • People who have a history of glaucoma (a condition affecting eye pressure)
  • People who have a seizure disorder that is not well controlled
  • People who have a known allergy to local anaesthetics (numbing medications)
  • People who are currently taking a specific class of heart rhythm medications known as Class III antiarrhythmics (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Alan Peterson, PhD, The University of Texas Health Science Center at San Antonio

Phone: 210-562-6726

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The University of Texas Health Science Center at San Antonio
Registry
ClinicalTrials.gov
Start date
26 February 2024
Est. completion
31 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5); Change from baseline in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov